Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Exact Sciences, colorectal cancer
Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending
The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a small study.
ESMO 2024: Exact Sciences unveils results from cancer algorithm trial
The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting algorithm.
Exact Sciences spikes ahead of data for blood-based cancer test
Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more here.
Exact Sciences says data support its colon cancer blood test
Recommended Reading Guardant wins FDA approval for colon cancer blood test
Exact
Sciences
released data from a study of its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced ...
ESMO: Exact Sciences shows off early colorectal cancer blood test data
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical data showing its blood-based test can help spot growing tumors | Presented at the annual meeting of the European Society for Medical Oncology,
STAT
4d
Biotech feud over the multibillion-dollar cancer blood test market spills onto social media
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...
FiercePharma
7d
Exact Sciences debuts first Spanish-language Cologuard ads to drive colon cancer screening in Latino community
Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from
Exact
Sciences
has a new campaign ...
6d
Buy Rating for Exact Sciences: Promising CRC Screening Test Outperforms with High Accuracy and Market Potential
Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...
6d
Exact Sciences Unusual Options Activity For September 16
In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...
Morningstar
4d
Exact Sciences Corp EXAS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
6d
Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
colorectal cancer
Trade
Feedback